logo-loader

Faron Pharmaceuticals provides insight on phase III trial

Published: 05:31 20 Dec 2018 EST

Faron Pharmaceuticals Ltd (LON:FARN) now understands why its phase III clinical trial on patients with acute respiratory distress syndrome didn’t yield the anticipated results. Faron's CEO Dr. Markku Jalkanen tells Proactive London's Polly Middlehurst what else could be extrapolated from the study and what the company intends to focus on now as a result. News here too on Faron's other project concerning immune-suppressant agents. Jalkanen adds, “While analysis continues, we believe the mixed results seen were due to a higher than anticipated placebo responses due to high pneumonia portion."

Faron Pharmaceuticals outlines groundbreaking work in cancer treatment -...

Dr. Markku Jalkanen, CEO of Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF), delivered a pivotal presentation on the company's groundbreaking work in cancer treatment, focusing on the reprogramming of myeloid cells to combat cancer at the Proactive One2One Investor Conference. Myeloid...

on 02/01/2024